Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET

Company Participants

Matthew Scalo - SVP, Investor Relations

Paul Diaz - CEO, President & Director

Nicole Lambert - COO

Bryan Riggsbee - EVP, CFO & Treasurer

Mark Verratti - Chief Commercial Officer.

Conference Call Participants

Tom Stevens - Cowen and Company

Jack Meehan - Nephron Research

Operator

Greetings, and welcome to the Myriad Genetics Fourth Quarter 2022 Financial Earnings Conference Call. During the presentation, all participants will be in a listen-only mode. Afterwards we will conduct a question and answer session. [Operator Instructions]. As a reminder, this conference is being recorded, Tuesday, February 28, 2023.

I would now like to turn the conference over to Matt Scalo. Please go ahead.

Matthew Scalo

Okay. Good afternoon, and welcome to the Myriad Genetics' Four Quarter and Full Year 2022 Earnings Call. During the call, we will review financial results we released today. And afterwards, we'll host a Q&A session. Our quarterly earnings release was issued this morning in Form 8-K and can be found on our website at investor.myriad.com.

I'm Matt Scalo, Senior Vice President of Investor Relations. And on the call with me today are Paul Diaz, our President and Chief Executive Officer; Bryan Riggsbee, our Chief Financial Officer; Nicole Lambert, our Chief Operating Officer and Mark Verratti, our Chief Commercial Officer.

This call can be heard live via webcast at investor.myriad.com. And a recording will be archived in the investor section of our website along with this slide presentation. Please note that some of the information presented today contains projections or other forward-looking statements regarding future events, or the future financial performance of the company.

These statements are based on management's current expectations, and the actual events or results may differ materially and adversely from these expectations for a variety of reasons. We refer you to the documents the company files from time to time with the SEC, specifically, the company's annual report on Form 10-K, it’s quarterly reports on Form 10-Q and the current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in our projections, or forward looking statements.

With that, I'll turn the call over to Paul.

Paul Diaz

Thanks, Matt. Good afternoon, everyone. And thank you for joining us. On today's call, we will discuss highlights from the fourth quarter and full year. We will also provide updates on the strategic initiatives that are driving our long-term growth plan.